


**Figure 1. Flow of participants**



*Legend:*

PA – primary aldosteronism

PAC – plasma aldosterone concentration

PRA – plasma renin activity

Index test criteria – PAC > 20 ng/dL plus PRA < 0.6 ng/ml/hr with spontaneous hypokalemia

**Table 1. Clinical characteristics between primary aldosteronism (PA) and non-PA patients (n=120)**

|  | All<br>(n=120)                         | PA<br>(n=79)             | Non-PA<br>(n=41)         | p-value |
|--|--|--------------------------|--------------------------|---------|
|  | Mean ± SD; Median (IQR); Frequency (%) |                          |                          |         |
| Age, years   | 49.94±11.00                            | 48.92±11.75              | 51.90±9.21               | 0.131*  |
| Sex at birth   |  |                          |                          | 0.888** |
| Male   | 42 (35.0)                              | 28 (35.4)                | 14 (34.1)                |         |
| Female   | 78 (65.0)                              | 51 (64.6)                | 27 (65.9)                |         |
| Hypertension   | 101 (91.8)                             | 70 (93.3)                | 31 (88.6)                | .462†   |
| Diabetes mellitus  | 32 (29.9)                              | 24 (33.3)                | 8 (22.9)                 | .267**  |
| Chronic kidney disease                                       |  |                          |                          | .681**  |
| Stage (based from 2021                                       |  |                          |                          |         |
| CKD-EPI eGFR ml/min/1.73<br>m <sup>2</sup> ) (n=102)         |  |                          |                          |         |
| G1 ( $\geq$ 90)  | 59 (57.8)                              | 37 (54.4)                | 22 (64.7)                |         |
| G2 (60-89)   | 31 (30.4)                              | 23 (33.8)                | 8 (23.5)                 |         |
| G3a (45-59)  | 10 (9.8)                               | 7 (10.3)                 | 3 (8.8)                  |         |
| G3b (30-44)  | 2 (2.0)                                | 1 (1.5)                  | 1 (2.9)                  |         |
| Spontaneous hypokalemia                                      | 71 (61.2)                              | 51 (65.4)                | 20 (52.6)                | .186**  |
| Baseline plasma<br>aldosterone concentration<br>(PAC), ng/dL | 18.49 (11.73-<br>27.67)                | 20.46 (13.73-<br>32.93)  | 13.25 (8.51-<br>23.21)   | 0.004‡  |
| Baseline plasma renin activity<br>(PRA), ng/ml/h             | 0.28 (0.15-<br>0.52)                   | 0.27 (0.15-<br>0.51)     | 0.29 (0.14-<br>0.54)     | 0.861‡  |
| Baseline Aldosterone-renin<br>ratio (ARR), ng/dL/ng/ml/h     | 62.29 (32.09-<br>140.75)               | 76.36 (36.21-<br>145.29) | 40.59 (31.08-<br>107.22) | 0.059‡  |

Statistical tests used: \*, Independent t-test; \*\*, Pearson Chi-Square test; †, Fisher's Exact test;  
‡, Mann-Whitney U test

**Table 2. CT-scan findings and histopathology in patients with positive saline infusion test (n=79)**

|                          | Frequency (%) |
|--------------------------|---------------|
| Abdominal CT done        | 65 (82.3)     |
| Laterality               |               |
| Bilateral nodule         | 5 (7.69)      |
| Unilateral nodule        | 48 (73.85)    |
| No discrete nodule seen  | 12 (18.46)    |
| Surgery done             | 19 (24.1)     |
| Histopathology           |               |
| Adrenocortical adenoma   | 14 (73.68)    |
| Adrenocortical carcinoma | 1 (5.26)      |
| Adrenocortical neoplasm  | 2 (10.53)     |
| Endothelial cyst         | 1 (5.26)      |
| Missing histopathology   | 1 (5.26)      |

**Table 3. Diagnostic performance of laboratory findings for primary aldosteronism**

|  | Sensitivity,<br>%             | Specificity,<br>%               | PPV, %                        | NPV, %                        | LR+                         | LR-                         | Accuracy,<br>%                |
|--|-------------------------------|---------------------------------|-------------------------------|-------------------------------|-----------------------------|-----------------------------|-------------------------------|
|  | Estimate (95% CI)             |                                 |                               |                               |                             |                             |                               |
| <b>3 combinations</b>  |                               |                                 |                               |                               |                             |                             |                               |
| A1:<br>PAC > 10<br>ng/dL + PRA <<br>1.0 ng/dL/hr +<br>spont. hypoK | 48.00%<br>(36.31 –<br>59.85%) | 69.70%<br>(51.29 –<br>84.41%)   | 78.26%<br>(67.09 –<br>86.44%) | 37.10%<br>(30.13 –<br>44.64%) | 1.58<br>(0.90 -<br>2.80)    | 0.75<br>(0.55<br>–<br>1.02) | 54.63%<br>(44.76 -<br>64.24%) |
| A2:<br>PAC > 15<br>ng/dL + PRA <<br>1.0 ng/dL/hr +<br>spont. hypoK | 44.00%<br>(32.55 -<br>55.94%) | 81.82%<br>(64.54 –<br>93.02%)   | 84.62%<br>(71.85 –<br>92.22%) | 39.13%<br>(33.20 –<br>45.40%) | 2.42<br>(1.12<br>–<br>5.21) | 0.68<br>(0.53<br>–<br>0.89) | 55.56%<br>(45.68 -<br>65.12%) |
| A3:<br>PAC > 20<br>ng/dL + PRA <<br>1.0 ng/dL/hr +<br>spont. hypoK | 34.67%<br>(24.04 -<br>46.54%) | 87.88%<br>(71.80 -<br>96.60%)   | 86.67%<br>(71.14 –<br>94.49%) | 37.18%<br>(32.47 –<br>42.15%) | 2.86<br>(1.08 -<br>7.54)    | 0.74<br>(0.60<br>–<br>0.92) | 50.93%<br>(41.13 -<br>60.67%) |
| A4:<br>PAC > 25<br>ng/dL + PRA <<br>1.0 ng/dL/hr +<br>spont. hypoK | 26.67%<br>(17.11 -<br>38.14%) | 100.00%<br>(89.42 -<br>100.00%) | 100.00%                       | 37.65%<br>(34.36 –<br>40.75%) | -                           | 0.73<br>(0.64<br>–<br>0.84) | 49.07%<br>(39.33 –<br>58.87%) |
| A5:<br>PAC > 10<br>ng/dL + PRA <<br>0.6 ng/dL/hr +<br>spont. hypoK | 45.33%<br>(33.79 –<br>57.25%) | 72.73%<br>(54.48 -<br>86.70%)   | 79.07%<br>(67.24 –<br>87.43%) | 36.92%<br>(30.39 –<br>43.98%) | 1.66<br>(0.90<br>–<br>3.06) | 0.75<br>(0.56<br>–<br>1.01) | 53.70%<br>(43.85 –<br>63.35%) |
| A6:<br>PAC > 15<br>ng/dL + PRA <<br>0.6 ng/dL/hr +<br>spont. hypoK | 41.33%<br>(30.08 -<br>53.30%) | 87.88%<br>(71.80 –<br>96.60%)   | 88.57%<br>(74.84 -<br>95.28%) | 39.73%<br>(34.41 -<br>45.30%) | 3.41<br>(1.31<br>–<br>8.88) | 0.67<br>(0.53<br>–<br>0.84) | 55.56%<br>(45.68 –<br>65.12%) |
| A7:<br>PAC > 20<br>ng/dL + PRA <<br>0.6 ng/dL/hr +<br>spont. hypoK | 34.67%<br>(24.04 -<br>46.54%) | 93.94%<br>(79.77 -<br>99.26%)   | 92.86%<br>(76.61 –<br>98.10%) | 38.75%<br>(34.43 –<br>43.25%) | 5.72<br>(1.44 -<br>22.71)   | 0.70<br>(0.58<br>–<br>0.84) | 52.78%<br>(42.94 -<br>62.46%) |
| A8:<br>PAC > 25<br>ng/dL + PRA <<br>0.6 ng/dL/hr +<br>spont. hypoK | 26.67%<br>(17.11 -<br>38.14%) | 100.00%<br>(89.42 -<br>100.00%) | 100.00%                       | 37.50%<br>(34.36 –<br>40.75%) | -                           | 0.73<br>(0.64<br>–<br>0.84) | 49.07%<br>(39.33 –<br>58.87%) |
| <b>2 Combinations</b>  |                               |                                 |                               |                               |                             |                             |                               |
| B1:<br>PAC > 10<br>ng/dL + PRA <                                   | 78.67%<br>(67.68 -<br>87.29%) | 34.29%<br>(19.13 –<br>52.21%)   | 71.95%<br>(66.27 –<br>77.01%) | 42.86%<br>(28.51 –<br>58.52%) | 1.20<br>(0.92 -<br>1.56)    | 0.62<br>(0.33<br>–<br>-)    | 64.55%<br>(54.85 -<br>73.43%) |

|  | Sensitivity,<br>%             | Specificity,<br>%             | PPV, %                        | NPV, %                        | LR+                           | LR-                         | Accuracy,<br>%                |
|--|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------|-------------------------------|
|  | Estimate (95% CI)             |                               |                               |                               |                               |                             |                               |
| 1.0 ng/dL/hr                                     |                               |                               |                               |                               | 1.17)                         |                             |                               |
| B2:<br>PAC > 15<br>ng/dL + PRA <<br>1.0 ng/dL/hr | 66.67%<br>(54.83 –<br>77.14%) | 60.00%<br>(42.11 –<br>76.13%) | 78.12%<br>(69.78 –<br>84.67%) | 45.65%<br>(35.59 –<br>56.09%) | 1.67<br>(1.08 -<br>2.58)      | 0.56<br>(0.37<br>-<br>0.84) | 64.55%<br>(54.85 -<br>73.43%) |
| B3:<br>PAC > 20<br>ng/dL + PRA <<br>1.0 ng/dL/hr | 49.33%<br>(37.58 –<br>61.14%) | 77.14%<br>(59.86 -<br>89.58%) | 82.22%<br>(70.70 –<br>89.86%) | 41.54%<br>(34.78 –<br>48.63%) | 2.16<br>(1.13 -<br>4.14)      | 0.66<br>(0.49<br>-<br>0.88) | 58.18%<br>(48.39 -<br>67.52%) |
| B4:<br>PAC > 25<br>ng/dL + PRA <<br>1.0 ng/dL/hr | 41.33%<br>(30.08 -<br>53.30%) | 88.57%<br>(73.26 -<br>96.80%) | 88.57%<br>(74.78 –<br>95.30%) | 41.33%<br>(36.02 –<br>46.85%) | 3.62<br>(1.38 -<br>9.45)      | 0.66<br>(0.53<br>-<br>0.83) | 56.36%<br>(46.58 -<br>65.80%) |
| B5:<br>PAC > 10<br>ng/dL + PRA <<br>0.6 ng/dL/hr | 65.33%<br>(53.46 –<br>75.96%) | 40.00%<br>(23.87 –<br>57.89%) | 68.18%<br>(58.62 –<br>76.74%) | 35.00%<br>(24.41 –<br>47.30%) | 1.09<br>(0.79 -<br>1.49)      | 0.87<br>(0.52<br>-<br>1.44) | 57.27%<br>(47.48 -<br>66.66%) |
| B6:<br>PAC > 15<br>ng/dL + PRA <<br>0.6 ng/dL/hr | 53.33%<br>(41.45 –<br>64.95%) | 65.71%<br>(47.79 –<br>80.87%) | 68.18%<br>(58.62 –<br>76.74%) | 39.66%<br>(31.86 –<br>48.01%) | 1.56<br>(0.94 -<br>2.58)      | 0.71<br>(0.51<br>-<br>1.00) | 57.27%<br>(47.48 –<br>66.66%) |
| B7:<br>PAC > 20<br>ng/dL + PRA <<br>0.6 ng/dL/hr | 41.33%<br>(30.08 -<br>53.30%) | 82.86%<br>(66.35 -<br>93.44%) | 83.78%<br>(70.38 –<br>91.83%) | 39.73%<br>(34.09 –<br>45.65%) | 2.41<br>(1.11 -<br>5.24)      | 0.71<br>(0.56<br>-<br>0.90) | 54.55%<br>(44.77 -<br>64.07%) |
| B8:<br>PAC > 25<br>ng/dL + PRA <<br>0.6 ng/dL/hr | 30.67%<br>(20.53 -<br>42.38%) | 97.14%<br>(85.08 -<br>99.93%) | 95.83%<br>(76.39 -<br>99.39%) | 39.53%<br>(35.76 –<br>43.44%) | 10.73<br>(1.51<br>-<br>76.32) | 0.71<br>(0.61<br>-<br>0.84) | 51.82%<br>(42.09 -<br>61.45%) |

*Legend:*

PAC – plasma aldosterone concentration  
 PRA – plasma renin activity  
 Spont. hypok – spontaneous hypokalemia  
 PPV – positive predictive value  
 NPV – negative predictive value  
 LR+ – positive likelihood ratio  
 LR- – negative likelihood ratio